A pharmacy receives a clozapine prescription for a patient, Hieronymus Vasquez, enrolled in the Clozapine REMS. The accompanying laboratory report shows an absolute neutrophil count that the prescriber has authorised as acceptable for continued treatment, but the pharmacy system has not yet received a current REMS authorisation status for this fill. What is the technician's correct next step before dispensing?
- ADispense immediately, since a prescriber-authorised acceptable neutrophil count is sufficient on its own to release clozapine.
- BDispense a partial supply now and verify the REMS authorisation status afterwards, treating it as a bridge to avoid delaying the patient's therapy.
- CConfirm a current Clozapine REMS authorisation for this fill before dispensing, since the certified pharmacy must verify authorisation alongside the neutrophil count. Correct
- DSubstitute a non-REMS antipsychotic of the pharmacy's own choosing to bridge the patient until the authorisation eventually arrives.
Why A is wrong: An acceptable count is necessary but not sufficient; the pharmacy must also confirm a current REMS authorisation, so relying on the count alone skips a required check.
Why B is wrong: Splitting the supply does not satisfy the programme; verification must occur before any quantity is released, so dispensing first and checking later is non-compliant.
Why C is correct: Correct: under the Clozapine REMS a certified pharmacy must verify a current authorisation status for the fill in addition to an acceptable absolute neutrophil count, so dispensing is held until that authorisation is confirmed.
Why D is wrong: Technicians cannot select a therapeutic substitute, and switching agents is a clinical decision; this bypasses both scope limits and the REMS requirement rather than resolving it.